



Drug Discovery 2017

ACC, LIVERPOOL

3rd - 4th October 2017



#ELRIGDD17

Event Platinum Sponsor:



Supported by:



THE
ROYAL
SOCIETY



SiLA
Rapid Integration®

www.elrig.org

Welcome To Drug Discovery 2017



As Scientific Program chairs it is our great pleasure to welcome you to Liverpool and the 11th Annual ELRIG Drug Discovery event.

Through the efforts of our volunteer organising committee, we have been able to assemble a world-class line up of scientific speakers organised into 6 thematic tracks over 2 days. Some, like our Innovations in Assay Design, Development & Screening and Innovations in Chemistry sessions will be recognisable from previous years. Others, such as our Advances in Imaging, and From Molecules to Man: Right Dose, First Time tracks are new and reflect hot topics and trends in the Drug Discovery Field. With two exciting plenary lectures, over 50 session speakers, 180 posters and a vibrant exhibition hall we are sure there will be something for all!

Once again, this year's venue, the Liverpool Echo Arena, is a fantastic place for us to convene. The state of the art conference facilities positioned close to one of the UKs most historic and eclectic city centres provide a perfect backdrop for the scientific and networking interactions upon which ELRIG is founded. The excellent travel links to Liverpool will hopefully see you arrive fresh and energised!

We would like to thank, in particular, Rhona Bennett, Clare Cockerham and Tara Shanks for their fantastic contribution in shepherding ourselves and the Program Chairs through the organising process. Without their help, together with the ELRIG back office and volunteers, this meeting would not be possible.

Without you, the meeting delegate, we have nothing too. We thank you in advance for your participation and look forward to connecting with you over the next couple of days. As always, we welcome your feedback on how we can further improve the agenda to ensure the growth and success of ELRIG DD for the future. Have fun in Liverpool, and enjoy the opportunity to discuss emerging Science within a vibrant and collegiate environment!



Steven Charlton
(University of Nottingham)



Tim Hammonds
(Cancer Research)



Rachel Grimley
(AstraZeneca)

A message from the ELRIG Chair Steve Rees

ELRIG is pleased to be returning to Liverpool for the 11th Drug Discovery meeting.



The meeting program, created by Rachel Grimley (AstraZeneca), Tim Hammonds (Cancer Research Technology), and Steve Charlton (University of Nottingham), contains six outstanding scientific sessions with presentations describing innovation in target validation, drug discovery and disease mechanisms. We are delighted to welcome our two keynote speakers, Dr Mene Pangalos, Executive Vice-president of the Innovative Medicines Biotech Unit at AstraZeneca and Dr Nessa Carey, International Director at PraxisUnico. We also welcome a number of partner organisations to the meeting; the British Pharmacological Society is presenting a workshop introducing opportunities for academic scientists to advance drug discovery projects through engagement with academic and industry drug discovery initiatives. SiLA are presenting a workshop discussing the impact of automation and informatics on the laboratory of the future, and the Royal Society are hosting a breakfast event. Alongside the scientific program we welcome the 70 companies participating in the exhibition and the innovation zone and the many scientists presenting their work in the poster exhibition.

Central to the mission of ELRIG is the delivery of high-quality scientific events that enable learning and networking to advance collaboration to further the science and technology of drug discovery. A defining feature of ELRIG is that our meetings continue to be free to attend. This is only possible due to the volunteers who freely give their time to organise and contribute to our events, and of course to the companies who provide sponsorship through exhibition at our meetings, all of whom have our deepest thanks.

ELRIG has presented two outstanding scientific meetings in 2017. For the first time the Research and Innovation meeting was held in Cambridge and welcomed over 400 delegates. In May ELRIG returned to Gothenburg for the Cell Based Assays meeting attended by almost 300 delegates. Alongside these events the ELRIG Science Strategy, Delegate Outreach and Exhibitor Outreach work groups led by Christine Williams, Fabrice Turlais and Kevin Moore have continued to develop events and other activities to meet the needs of ELRIG members. I am particularly proud of the launch of the ELRIG networking events. These are evening opportunities for scientists to discuss breaking science and to network in an informal environment. Over 250 scientists have attended such events in 2017 in Cambridge, Alderley Park, and Glasgow. Looking ahead to 2018 we will continue to run events in these locations and in science centres in Oxford and London.

During 2018 ELRIG will present five scientific meetings. In February the biannual Robotics and Automation meeting will take place at Festo in Stuttgart, Germany. In April the Research and Innovation meeting will return to Cambridge, in June we will be launching a new meeting, Discovery Technologies in Alderley Park and in November the biannual Pharmaceutical Flow Cytometry and Imaging meeting will return to GSK Stevenage. We are especially delighted to announce that the 2018 Drug Discovery meeting will be held in October at the EXCEL Arena bringing ELRIG's prestige meeting to London for the first time. The scientific program is being developed and we anticipate this to be the largest ELRIG meeting yet.

I would like to thank the many committed members of our science committees, our program chairs and the general committee who have worked tirelessly to develop ELRIG events in 2017. I would particularly like to thank the ELRIG office staff, Sanj Kumar the General Manager, Tara Shanks, Rhona Bennett and Clare Cockerham, without whom these meetings simply would not happen. Finally I would like to thank all of you for joining us in Liverpool, and hope to see you again at future ELRIG meetings

Kind regards

Steve Rees

ELRIG Chair



Drug Discovery 2017 Scientific Committee

Tuesday 3rd October 2017

Innovations In Assay Design,
Development & Screening



Helen Boyd
(AstraZeneca)



Florian Fuchs
(Novartis)



Chris Schofield
(University of Oxford)



Matt Tozer
(Cyclofluidic)

Wednesday 4th October 2017

Innovations in Chemistry



Richard Bayliss
(University of Leeds)



Neil Carragher
(University of Edinburgh)



Darren Cawkill
(Apollo Therapeutics)



Louise Jones
(MRC)

Advances In Imaging

Target Identification & Validation

Drug Discovery in the
4th Dimension

From Molecule to Man:
right dose, first time



Jon Hutchinson
(GlaxoSmithKline)



David Swinney
(iRND3)



Pinky Dua
(Pfizer)



Piet Van der Graaf
(Leiden University)

WI-FI at Drug Discovery 2017

WI-FI at ACC, Liverpool is free. Simply select the network **FREE_WIFI** to be connected.
There is no username or password.

Our Plenary Keynote Speakers

Dr. Mene Pangalos
(Executive Vice-President, IMED Biotech Unit, AstraZeneca)

“Transforming R&D productivity; How can we better turn science into medicine”
Tuesday 3rd October 2017: 08:45: ROOM 3




The future treatment for many of today's diseases lies in discovering new biology, understanding and challenging scientific hypotheses, to develop novel therapies. The advent of the genomics revolution brings with it an expanding list of pathways and targets to pursue - and with it new drug discovery challenges. Validating drug targets by understanding and challenging scientific hypotheses has never been more important. By combining new technologies, focusing on medical understanding, challenging scientific hypotheses and driving strategic private and academic partnerships we are making real progress in our ability to define and prosecute novel treatment approaches for a variety of complex diseases.

A member of the company's Senior Executive team, Mene has overall responsibility for the company's pharmaceutical discovery research and early development activities. Since joining AstraZeneca in 2010, Mene has been instrumental in rebuilding the company's commitment to science and scientific excellence. He has led the transformation of R&D productivity; driven deeper collaborations with academic, biotech and peer organisations; pioneered programmes to promote Open Innovation and fostered a science driven culture that rewards great science and truth-seeking behaviours. Mene retains an active interest in neurodegenerative disease and neuropharmacology and continues to mentor post docs and PhD students.

Mene has published more than 140 peer-reviewed articles in scientific journals and is an internationally renowned expert in neuroscience and drug discovery. He is a leading figure in UK science, serving on several Boards including the Medical Research Council, the National Centre for Universities and Business Council, the Ministers and Industry Strategy Group and the Cambridge Biomedical Campus Strategy Board. Mene is also overseeing the creation of AstraZeneca's new £330 million research centre in Cambridge – a state of the art facility designed to stimulate collaborative scientific innovation and which will play an important role in the future success of the UK life science industry.

Dr. Nessa Carey
Carey International Impact Training


“Big pharma – can we fix it?”
Wednesday 4th October 2017: 13:50: ROOM 3



Commentators seize on instances of bad practise in the pharmaceutical industry. So they should - all business sectors have a responsibility to behave with integrity. But the vitriol that is directed at pharma appears disproportionately excessive, especially for an industry that has saved and improved the lives of hundreds of millions of people. How have we reached a situation where one of the most important sectors affecting human health has become the enemy and an easy target? And more importantly, how do we reverse this? The speaker will argue that the issues identified by the most vocal opponents of the industry are symptoms of a deeper problem, not causes. In this session the speaker will offer her thoughts on how we have ended up in this situation and what we need to do to improve it while we still have the chance

Nessa Carey has a virology PhD from the University of Edinburgh and is a former Senior Lecturer in Molecular Biology at Imperial College, London. She worked in the biotech and pharmaceutical industry for thirteen years and is now International Director for the UK's leading organisation for technology transfer professionals. She lives in Norfolk and is a Visiting Professor at Imperial College.


ACC, Liverpool Floorplan



Exhibitor Booth Locations

4titude Ltd.	D4	Essen BioScience	A3	NanoTemper Technologies GmbH	H1
acCELLerate GmbH	D16	Eurofins Pharma Discovery Services	F4 & F5	NC3Rs	Innovation Zone
Agilent Technologies	D11	Euroscitech	G2	NCIMB Ltd	A2
Alpha MED Scientific Inc.	B13	Formulatrix	D12	Nexcelom Bioscience	D13, D14, D23, D24
Apley Technology Ltd	Innovation Zone	MedChemNet	Media Zone	NMI TT Pharmservices	B17
Axol Bioscience Ltd	F6	Genedata AG	B3	Oncodesign	G6
Beckman Coulter GmbH	F11 & F12	Greiner Bio One Ltd	C5	PAA	B15
BigNeat	D7	Hamamatsu Photonics UK Limited	D22	Peak Proteins	Innovation Zone
BioSero	B16	Hamilton	E4, E5 & E6	Pelago Bioscience	D5
Biostrata	Media Zone	HCS-pharma	Innovation Zone	Pivot Park Screening Centre	A4
BioSystems Technology Ltd	Innovation Zone	HighRes Biosolutions, Inc	H5	Porvair	F9
BioTek Instruments Limited	C1	Idea Bio-Medical Ltd	B14	Promega UK Ltd	E1
BlueCatBio GmbH	E2	Image Solutions (UK) Ltd	G3	ReproCELL Europe Ltd	H2
BMG LABTECH Ltd	F7 & F8	InSphero	C4	SAL Scientific Ltd	F2
Cambridge Bioscience	C3	Integra	B7 & B12	Sartorius Stedim Biotech	B6
Cambridge Research Biochemicals	D20	Intellicyt	D6	SB Drug Discovery	D8
Cell Signaling Technology	B1	Kbiosystems Limited	F10	Select Science	Media Zone
Cellular Dynamics	D9	Kirkstall	Innovation Zone	STEMCELL Technologies	H6
Censo Biotechnologies	Innovation Zone	Labcyte Inc.	B4 & B5	Stemtek Therapeutics	A7
Chemometec	D10	Lablogic Systems Ltd	D1	Sygnature Discovery	D2
Cisbio	D19	Langton Howarth	Careers Zone	Takara Bio	F1
Collaborative Drug Discovery	A1	LGC-ATCC	D15	Tecan UK Ltd	B9 & B10
Corning Life Sciences	D21	Liconic UK	B8	Technology Networks	Media Zone
CytoSMART	Innovation Zone	Lifearc	B2	Titian Software Ltd	H3
DefiniGEN	Innovation Zone	Medicines Discovery Catapult	F3	UK Pharmacogenetics &	
DiscoverX	E3	Merck	A5 & A6	Stratified Medicine Network	Media Zone
Dreamtek & The Virtual Forge	Innovation Zone	Meso Scale Discovery	C2	UKSPA	Media Zone
Drug Discovery News	Media Zone	Miltenyi Biotec	D3	University of Leicester	H4
Drug Discovery World	Media Zone	Mimetas BV	D17	UPM-Kymmene Corporation	B11
Drug Target Review	Media Zone	MIP Diagnostics Limited	B18	Wildcat Laboratory Services	F10
ELRIG	G1	Molecular devices	D18	Zyme Communications	Media Zone
ENAMINE Ltd.	G5	Moleculomics Ltd	Innovation Zone		

Drug Discovery 2017- Exhibition Hall Floorplan



WI-FI at Drug Discovery 2017

WI-FI at ACC, Liverpool is free. Simply select the network **FREE_WIFI** to be connected.
There is no username or password.

ELRIG Mobile App


Download the free ELRIG app and access all our conference information, programme and more from your phone or tablet.

- view the event programme, presentation and poster abstracts and speaker profiles
- view exhibitor video presentations
- view the exhibitor guide
- view the delegate and exhibitor list
- organise your day with your own favourites list
- share your profile as vCard and QR Code and scan exhibitor QR code information tags.
- network – contact delegates, other exhibitors and speakers easily through opt-in directories and integration with Linked-In, Twitter and Facebook

To download the ELRIG app, visit the app store appropriate to your tablet or smart phone, scan the QR code or visit the ELRIG website: www.elrig.org/mobile-app/



Poster Competition



The form is titled 'Drug Discovery 2017 ACC, LIVERPOOL 3rd-4th October 2017'. It features a silhouette of the Liverpool skyline. The 'VOTING' section includes two prize categories: 'THE ELRIG TECHNOLOGY PRIZE' and 'THE ELRIG POSTER PRIZE'. Each category has a text box for the user to describe their choice. Below these, a note states 'All votes will be entered into a prize draw for an Amazon Echo Dot at the closing session'. A section for returning the form to the ELRIG desk by 'AFTERNOON COFFEE BREAK on Day 2 - Thank you!' includes a box for contact details (Name, Company, Mobile No., E-mail) and the website 'www.elrig.org'.

Every year at ELRIG Drug Discovery we get a fantastic range of Posters presented. We invite YOU, the delegates, to vote for what you think is the best poster. Simply fill in your choice on the voting form in your programme and return it to the ELRIG registration desk.

The winner will be announced in the closing address in Room 3 at 16:40 on Wednesday 4th October. Votes returned by 3pm on Wednesday 4th will be entered into a PRIZE DRAW which will also be made at the closing address.

(Please note you need to be there in person to win)

Technology Prize

Please have a good look around the exhibition: it's the exhibitors' support that keeps ELRIG events free to attend. We invite YOU, the delegates, to vote for what you think is the best technology being shown in the exhibition.

Fill in your choice on the voting form in your programme and return it to the ELRIG registration desk. The winner will be announced in the closing address (Room 3 - 16:45 on Friday 14th October). Votes returned by 3pm on Friday 14th will be entered into a PRIZE DRAW – also made at the closing address. (Again please note that you need to be there to win).





BRITISH
PHARMACOLOGICAL
SOCIETY

TODAY'S
SCIENCE
TOMORROW'S
MEDICINES

Register today

PHARMACOLOGY 2017

11–13 December 2017

The Queen Elizabeth II Conference Centre, London



Symposia: Cardiovascular and Respiratory Pharmacology | Neuropharmacology
Integrated Systems Pharmacology | Molecular and Cellular Pharmacology
Toxicology & Drug Discovery, Development and Evaluation

For more information and to register please visit
www.bps.ac.uk/pharmacology2017



Session Summary



Innovations In Assay Design, Development & Screening

Tuesday 3rd October 2017: ROOM 3

Over the past 5 years the screening landscape to find tools and hits has changed dramatically as new assay technologies step into the limelight. No longer are screens run using simple reads outs, but are more often multi-parametric in nature and generate large volumes of data. This evolution to more disease relevant assays and screens has been observed mostly in the area of cell based assays as imaging becomes the “norm” along with the use of transcriptomics and precise genome editing.

Alongside this change the types of cells and cellular systems being used in screening has moved away from recombinant cell lines and this presents both opportunities and challenges in terms of the assay development plus the scale and outcome of a screen. The other dimension which is changing concerns the growing number of new modalities in drug discovery alongside traditional small molecules. In this session we would like to give you a flavour of many of these new and exciting areas.

**SNAPSHOTS
SPONSORED BY:**



Session Chairs: Helen Boyd (AstraZeneca) & Florian Fuchs (Novartis)		
08:40 - 08:45	Introduction to Plenary Keynote	
08:45 - 09:30	PLENARY KEYNOTE: ROOM 3	
	Dr Mene Pangalos Executive Vice-President IMED Biotech Unit, AstraZeneca	Transforming R&D productivity; How can we better turn science into medicine
09:30 - 09:45	Florian Fuchs (Novartis)	Session Chairs Welcome and Introductions
09:45 - 10:30	Session Keynote: Petra Kluger Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB	Biofabrication of Human Tissue Models
10:30 - 11:00	Paul Datlinger CeMM Research Center for Molecular Medicine, Vienna	CROP-seq - Pooled CRISPR screens with single-cell transcriptome readout
11:00 - 11:30	COFFEE BREAK - VENDOR SPOTLIGHT: TTP Labtech	
11:30 - 12:00	Olivier Frey InSphero	A Microphysiological System Built For 3D Microtissue Spheroids
12:00 - 12:15	POSTER SPOTLIGHTS	
12:15 - 12:45	Christoph Dumelin Novartis Pharma AG	Encoded peptide libraries in drug discovery
12:45 - 14:00	LUNCH - EXHIBITION - POSTERS	
14:00 - 14:30	Helena Peilot Sjögren AstraZeneca	Understanding mode of action using BRET & FRET cell based assays to investigate MALT1 proteolytic & scaffolding function
14:30 - 15:00	SNAPSHOT PRESENTATION: Nexcelom	
15:00 - 15:45	COFFEE BREAK	
15:45 - 16:15	Ali Tavassoli University of Southampton	A platform for the generation and high throughput screening of cyclic peptide libraries
16:15 - 16:45	Joanne Shearer Charles River Laboratories	Development of an HTS assay for modulation of enzyme function in tissue preparations
16:45 - 16:55	POSTER SPOTLIGHTS	
16:55 - 17:00	SNAPSHOT PRESENTATION: Intellicyt	
17:00 - 19:00	DRINKS RECEPTION - NETWORKING - POSTERS	

Session Summary

#ELRIGDD17

Drug Discovery In The 4th Dimension

Tuesday 3rd October 2017: HALL 1C

Drug discovery in the 4th dimension will give the audience a better understanding of the potential value of binding kinetics to drug discovery and the challenges to realise the value. Most target-based discovery programmes optimise compounds using measures of potency or affinity at equilibrium. However, a significant proportion of approved drugs operate by non-equilibrium mechanisms within their therapeutic context. One determinant of non-equilibrium conditions is slow dissociation kinetics (long residence time), which can extend the pharmacodynamic effect beyond the half-life of the drug, provide kinetic selectivity over other targets and/or give an efficacy advantage where the drug competes with an endogenous ligand or substrate under non-equilibrium conditions. These potential advantages, which directly affect the drug's therapeutic index and utility, are becoming more widely appreciated and experimental methods for measuring binding kinetics in higher throughput have advanced. The questions posed in this session are whether the timely and rational application of drug-target binding kinetics remains an unrealised opportunity in drug discovery, with the potential to reduce attrition? Can we define an optimum kinetic profile and build it in during lead optimisation?

**SNAPSHOTS
SPONSORED BY:**



Session Chairs: Jon Hutchinson (GlaxoSmithKline) & David Swinney (iRND3)		
08:40 - 08:45	Introduction to Plenary Keynote	
08:45 - 09:30	PLENARY KEYNOTE: ROOM 3	
	Dr Mene Pangalos Executive Vice-President IMED Biotech Unit, AstraZeneca	Transforming R&D productivity; How can we better turn science into medicine
09:30 - 09:45	Jon Hutchinson (GlaxoSmithKline)	Session Chairs Welcome and Introductions
09:45 - 10:30	Session Keynote: David Swinney iRND3	The value of binding kinetics to drug discovery
10:30 - 11:00	Chun-wa Chung GlaxoSmithKline	How to measure and interpret the “fourth” dimension
11:00 - 11:30	COFFEE BREAK - VENDOR SPOTLIGHT: TTP Labtech	
11:30 - 12:00	Kelly Gatfield GlaxoSmithKline	NanoBRET: An experimental approach to monitoring binding kinetics in cells
12:00 - 12:15	SNAPSHOT PRESENTATIONS: Genedata AG, Corning Life Sciences, Promega UK Ltd	
12:15 - 12:45	Yibing Shan D E Shaw Research	Making use of molecular dynamics simulations in structure-based design of kinase drugs
12:45 - 14:00	LUNCH - EXHIBITION - POSTERS	
14:00 - 14:30	Gerhard Mueller Gotham Therapeutics	Optimizing Binding Kinetics in Medicinal Chemistry: facts or fantasy?
14:30 - 14:45	POSTER SPOTLIGHTS	
14:45 - 15:00	SNAPSHOT PRESENTATIONS: BMG LABTECH Ltd, Cellular Dynamics Intl, Hamilton	
15:00 - 15:45	COFFEE BREAK	
15:45 - 16:15	Rob Cooke Heptares	Deciphering GPCR-ligand interactions through structural and biophysical investigations
16:15 - 16:45	Peter Tonge Stony Brook University	Improving the Prediction of In vivo Drug Activity
16:45 - 17:00	POSTER SPOTLIGHTS	
17:00 - 19:00	DRINKS RECEPTION - NETWORKING - POSTERS	

Session Summary

#ELRIGDD17

Advances In Imaging

Tuesday 3rd October 2017: HALL 1B

New advances in, whole body, microscopic and molecular imaging hardware, functional imaging biosensors and sophisticated image-analysis and image-informatics methods are transforming the application of functional biology towards previously unattainable levels of high spatial, temporal and molecular resolution. Such developments are well placed to advance translational research studies applicable to multiple aspects of drug discovery and drug development phases. Imaging applications in drug discovery include: Clinical and preclinical proof-of-concept studies; Enabling the development and application of more complex and disease relevant cell- and tissue-based models; Target identification; Target validation and Innovative chemical design.

SNAPSHOTS SPONSORED BY:



Pharma
Discovery Services



Session Chairs: Richard Bayliss (University of Leeds) & Neil Carragher (University of Edinburgh)		
08:40 - 08:45	Introduction to Plenary Keynote	
08:45 - 09:30	PLENARY KEYNOTE: ROOM 3	
	Dr Mene Pangalos Executive Vice-President IMED Biotech Unit, AstraZeneca	Transforming R&D productivity; How can we better turn science into medicine
09:30 - 09:45	Richard Bayliss , University of Leeds & Neil Carragher , University of Edinburgh	Session Chairs Welcome and Introductions
09:45 - 10:30	Session Keynote: Tony Ng Kings College London & University College London	Molecular Imaging of cancer in the future: Monitoring treatment response by imaging oncogenic rewiring and immune microenvironment changes, through combining whole body imaging with tissue / exosome-based approaches
10:30 - 11:00	Shonit Punwani Centre for Medical Imaging-UCL	Advances in Magnetic Resonance Imaging of cancer: translating from concept to clinical application
11:00 - 11:30	COFFEE BREAK - VENDOR SPOTLIGHT: TTP Labtech	
11:30 - 12:00	Kevin Brindle University of Cambridge	Detecting early tumour responses to treatment using molecular imaging
12:00 - 12:15	SNAPSHOT PRESENTATIONS: Merck, BioTek Instruments Ltd, LGC ATCC	
12:15 - 12:45	Bram Herpers Ocellio B.V.	Phenotypic screening of anti-cancer agents in 3D-cultured human tissues
12:45 - 14:00	LUNCH - EXHIBITION - POSTERS	
14:00 - 14:30	Neil Carragher University of Edinburgh	Multiparametric High-Content Cell Imaging and Image-Informatics: Advancing Phenotypic Drug Discovery
14:30 - 14:45	POSTER SPOTLIGHTS	
14:45 - 15:00	SNAPSHOT PRESENTATIONS: Eurofins Pharma Discovery Services, Sygnature Discovery, Tecan	
15:00 - 15:45	COFFEE BREAK	
15:45 - 16:15	Neil Ranson University of Leeds	Cryo-EM as a tool in modern biomedical discovery
16:15 - 16:45	Charlotte Dodson Imperial College London	Dynamic equilibrium of Aurora-A kinase activation loop revealed by single molecule spectroscopy
16:45 - 17:00	POSTER SPOTLIGHTS	
17:00 - 19:00	DRINKS RECEPTION - NETWORKING - POSTERS	

Session Summary

 #ELRIGDD17

Workshop: Cutting-edge cellular analysis techniques: Case studies in drug discovery

Tuesday 3rd October 2017: 09:30 - 11:00 - ROOM 11A

Cellular analysis and cell-based assays are central to scientific discovery and the hunt for new biomedicines. Increasingly, more complex and advanced cell models are employed, including co-culture systems, iPSC-derived and patient specific tissue organoids. This raises the bar for assay development and functional profiling methods that are able to extract the deeper content provided by these models, without compromising efficiency and productivity.

In this workshop, we will discuss the latest developments in two ground breaking cellular analysis solutions: IncuCyte® live-cell analysis and iQue® Screener PLUS high throughput suspension cell analysis platform. Through industrial and academic end-user case study presentations, new applications of these technologies in drug discovery projects will be reviewed. These include immune-cell killing assays in 2D & 3D, antibody internalization measurements, clonal dilution workflows and tumour-spheroid analyses. Interactive discussions will be encouraged to explore how these platforms are best aligned with drug discovery project requirements and how they can be further developed to address unmet need.

The workshop is targeted toward researchers with general interest in translational cell models, cell-based assays, cancer biology and immunology, including current and prospective users.

WORKSHOP AGENDA		
09:30 – 09:35	Peter Djali (Intellicyt)	Welcome and Introductions
09:35 – 09:55	Bryan Miller (Sygnature Discovery)	Use of Live-Cell Imaging Assays for Immunology in Integrated Drug Discovery Programmes
09:55 – 10:15	Rachel Forfar (LifeArc)	Developing an Assay Platform for Screening and Characterisation of Antibody Drug Conjugates
10:15 – 10:35	Rosemary Burke (The Institute of Cancer Research)	Use of IncuCyte® Live-Cell Analysis in Cancer Drug Discovery Programs
10:35 – 11:00	Del Trezise (Essen BioScience)	What's new with IncuCyte® and iQue Screener®?: Focus on Immunology & 3D spheroids
11:00 - 11:30	COFFEE BREAK - End of Workshop	



Session Summary

 #ELRIGDD17

SLAS Author Workshop: How to Get Your Work Published

Tuesday 3rd & Wednesday 4th October 2017: 12:45 -14:00 - Exhibition Hall

OVERVIEW

There is no magic bullet, but there are important tips that every prospective author should know before submitting a scientific manuscript for consideration by a peer-reviewed journal. Rob Howes, PhD, of AstraZeneca (and member and guest editor of the SLAS Discovery Editorial Board), will share step-by-step advice on how to design and write scientific research papers more clearly and effectively to improve their chances for successful publication. Learn what editors want, what they don't want, common mistakes, insider tips and how reviewers evaluate manuscripts.

The format of the session will be a presentation by Dr. Howes followed by a Question & Answer session and discussion.

ROB HOWES



Rob Howes, Ph.D., has been with AstraZeneca since late 2016 where he is the director of Reagents and Assay Development within Discovery Sciences in Sweden. He has more than 20 publications and has been an invited speaker for more than 30 scientific venues. He has been a member of the *SLAS Discovery* Editorial Board since 2015 and served as guest editor for a special issue on Therapeutic Antibody Discovery and Development.

Rob started his industrial career in 2001 at Vernalis, a UK biotech company focused on developing cancer therapeutics using structure-based drug design. He held various positions culminating in leading the HTS group as well as having impact on several small molecule research programmes. In 2008 he joined Horizon Discovery, a UK biotech company developing rAAV genome editing technology as research director. He built several teams and labs in the UK and Italy before transitioning as principal scientist to lead collaborations with over 50 academic groups across the globe. From 2013 to 2016 he was associate director at MedImmune in Cambridge, UK, leading the Biologics Profiling team.

Rob obtained his Ph.D. in Molecular Biology from the University of Cambridge studying EGF signaling under the mentorship of Matthew Freeman at the Medical Research Council's Laboratory of Molecular Biology. Prior to starting an industrial career, he completed Postdoctoral Fellowship's at Stanford University in the lab of Roel Nusse and later at the University of Cambridge in the lab of Sarah Bray studying the role of frizzled receptors in Wnt signaling.

Session Summary

 #ELRIGDD17

Innovations in Chemistry

Wednesday 4th October 2017: ROOM 3

Molecular methodology for medicinal chemistry appears to be close to undergoing a paradigm shift. This session aims to illustrate this possibility, by highlighting areas in which major recent advances have been, i.e. rationally directing target degradation, applying enormous libraries of peptides to challenging targets, automated synthesis, flow chemistry, artificial intelligence-driven discovery and ultra-rapid structural biology. As well as highlighting cutting edge research in these fields, our objective is to promote discussion at ELRIG and beyond as to how these and related methodological advances can best be applied to the efficient discovery of new medicines.

**SNAPSHOTS
SPONSORED BY:**



Session Chairs: Chris Schofield (University of Oxford) & Matt Tozer (Cyclofluidic)		
08:00 - 08:45	BREAKFAST WORKSHOPS	
08:45 - 09:00	Chris Schofield, University of Oxford & Matt Tozer, Cyclofluidic	Session Chairs Welcome and Introductions
09:00 - 09:45	Session Keynote: John Harling GlaxoSmithKline	Innovation in Medicinal Chemistry: Beyond Small-Molecule Inhibitors.
09:45 - 09:55	SNAPSHOT PRESENTATIONS: Miltenyi, Collaborative DD	
09:55 - 10:25	Floris Rutjes Radboud University	Continuous flow synthesis of small molecule heterocycle
10:25 - 10:30	SNAPSHOT PRESENTATION: LabLogic	
10:30 - 11:00	COFFEE BREAK	
11:00 - 11:30	Ian Baxendale University of Durham	The Application of Flow Chemistry for Target Synthesis
11:30 - 11:45	SNAPSHOT PRESENTATIONS: ENAMINE Ltd	
11:45 - 12:00	POSTER SPOTLIGHTS	
12:00 - 12:30	Clive Green AstraZeneca	The convergence of artificial intelligence and chemistry for drug discovery
12:30 - 13:45	LUNCH - EXHIBITION - POSTERS	
13:45 - 13:50	Introduction to plenary keynote speaker	
13:50 - 14:35	PLENARY KEYNOTE: ROOM 3	
	Dr. Nessa Carey Carey International Impact Training	Big pharma – can we fix it?
14:35 - 14:55	Peter Simpson Medicines Discovery Catapult	Medicines Discovery Catapult - how deep collaboration can re-energise the UK's drug discovery success
14:55 - 15:25	Akane Kawamura University of Oxford	Development of Selective and Potent Cyclic Peptides Targeting Histone Demethylases
15:25 - 15:40	POSTER SPOTLIGHTS	
15:40 - 16:10	Frank von Delft Diamond Light Source	X-ray Fragment Screening comes of age: 1000 crystals per week at Diamond's XChem facility
16:10 - 16:40	Allen Orville Diamond Light Source	Dynamic Structural Biology: Enabled by XFELs and Complementary Methods
16:40 - 17:00	CLOSE OF CONFERENCE & PRIZE DRAW - ROOM 3	

Session Summary

#ELRIGDD17

Target Identification and Validation

Wednesday 4th October 2017: HALL 1C

In drug discovery, selecting a specific molecular target/pathway to modulate and therefore alter a human disease process is the first and fundamentally critical step to success. As such, current approaches to identify and validate drug targets place an early emphasis on human translation. This session will begin by giving an expert overview of the current landscape around drug target ID and validation from both an industrial and academic perspective. The translational challenges posed to drug discovery scientists in both settings will be highlighted alongside some new and innovative funding strategies that aim to bridge basic biological research with industrial therapeutic application. Experts in the latest cutting edge technologies will report on how both single cell analysis and CRISPR/CAS9 are driving forward our ability to dissect the molecular mechanisms of disease and improve our understanding of drug targets. Target validation & ID will then be put into a clinical context, by reviewing two diverse areas of medical need that are in urgent need of novel validated targets; antimicrobial resistance and Alzheimer's disease.

**SNAPSHOTS
SPONSORED BY:**



INTEGRA



LABCYTE

NANO TEMPER



Session Chairs: Darren Cawkill (Apollo Therapeutics) & Louise Jones (MRC)		
08:00 - 08:45	BREAKFAST WORKSHOPS	
08:45 - 09:00	Darren Cawkill , Apollo Therapeutics & Louise Jones , MRC	Session Chairs Welcome and Introductions
09:00 - 09:45	Session Keynote: Steve Wedge Newcastle University	Target identification and validation in oncology: making basic science translationally relevant
09:45 - 09:55	SNAPSHOT PRESENTATIONS: Pelago Bioscience, Integra	
09:55 - 10:25	Frederic Bassilana Novartis	From potential targets to Targets with potential
10:25 - 10:30	SNAPSHOT PRESENTATION: Axol Bioscience Ltd	
10:30 - 11:00	COFFEE BREAK	
11:00 - 11:30	Maya Ghoussaini Open Targets, Wellcome Trust Sanger Institute	Using Human Genetics to make new medicines
11:30 - 11:50	SNAPSHOT PRESENTATIONS: Labcyte, Cambridge Bioscience, NanoTemper, Takara Bio	
11:50 - 12:00	POSTER SPOTLIGHTS	
12:00 - 12:30	Klio Maratou GlaxoSmithKline	Use of CRISPR for the interrogation of targets and pathways in cellular systems
12:30 - 13:45	LUNCH - EXHIBITION - POSTERS	
13:45 - 13:50	Introduction to plenary keynote speaker	
13:50 - 14:35	PLENARY KEYNOTE: ROOM 3	
	Dr. Nessa Carey Carey International Impact Training	Big pharma – can we fix it?
14:35 - 14:55	Peter Simpson Medicines Discovery Catapult	Medicines Discovery Catapult - how deep collaboration can re-energise the UK's drug discovery success
14:55 - 15:25	Mike Stubbington Wellcome Trust Sanger Institute	The Human Cell Atlas
15:25 - 15:40	POSTER SPOTLIGHTS	
15:40 - 16:10	Lee Dawson Astex Pharmaceuticals	Is the Amyloid Hypothesis Dead & What's the "next big thing" in Alzheimer's Disease Drug Discovery ?
16:10 - 16:40	Christopher Dowson University of Warwick	Creating the tools to tackle cell wall biosynthesis
16:40 - 17:00	CLOSE OF CONFERENCE & PRIZE DRAW - ROOM 3	

Session Summary

 #ELRIGDD17

From Molecule to Man: right dose, first time

Wednesday 4th October 2017: HALL 1B

Taking a molecule from laboratory to the human subject is a key step in drug development when potential new medicines are given to humans for the first time. It is an exciting phase to unravel how the molecule behaves in human but also comes with many challenges that need to be considered and evaluated prior to First in Human study. The safety and well-being of the subjects, whether they are healthy individuals or patients must always be a priority while designing these studies.

Understanding of the mechanism, confidence in translation from non-clinical data to the clinic, choosing relevant biomarkers, different considerations based on the modality of the molecule (small molecule, large molecule) being studied and regulatory guidance are all important factors to consider. Predicting the right dose of a drug, at the right time, to the right patient population is still a key challenge.

**SNAPSHOTS
SPONSORED BY:**



Session Chairs: Professor Piet van der Graaf (Certara & University of Leiden) & Pinky Dua (Pfizer)		
08:00 - 08:45	BREAKFAST WORKSHOPS	
08:45 - 09:00	Piet van der Graaf Certara & University of Leiden	Session Chairs Welcome and Introductions
09:00 - 09:45	Session Keynote: Amin Rostami University of Manchester	Physiologically-based pharmacokinetics (PBPK) to bridge between in vitro discovery and in vivo human studies
09:45 - 09:55	SNAPSHOT PRESENTATIONS: InSphero, ReproCELL	
09:55 - 10:25	Andy Davis AstraZeneca	Using the medicinal Chemistry Toolkit app - supporting good translational science in projects
10:25 - 10:30	SNAPSHOT PRESENTATION: NMI TT Pharmaservices	
10:30 - 11:00	COFFEE BREAK	
11:00 - 11:30	Neil Benson Certara QSP	PKTool; a free PKPD software tool to help decision making in early drug discovery
11:30 - 11:45	SNAPSHOT PRESENTATIONS	
11:45 - 12:00	POSTER SPOTLIGHTS	
12:00 - 12:30	Mark Fidock AstraZeneca	Diagnostic development today and in to the future
12:30 - 13:45	LUNCH - EXHIBITION - POSTERS	
13:45 - 13:50	Introduction to plenary keynote speaker	
13:50 - 14:35	PLENARY KEYNOTE: ROOM 3	
	Dr. Nessa Carey Carey International Impact Training	Big pharma – can we fix it?
14:35 - 14:55	Peter Simpson Medicines Discovery Catapult	Medicines Discovery Catapult - how deep collaboration can re-energise the UK's drug discovery success
14:55 - 15:25	Mario Van der Stelt Leiden Institute for Chemistry (LIC)	The role of discovery in first-in-human design: Chemical proteomics reveals off-target proteins of the fatal experimental drug BIA 10-2474
15:25 - 15:40	POSTER SPOTLIGHTS	
15:40 - 16:10	Stefano Zamuner GlaxoSmithKline	Monoclonal Antibody Tissue Distribution and Target Engagement using a Physiologically-Based Pharmacokinetic Framework
16:10 - 16:40	Pinky Dua Pfizer	Innovative first-in-human (FIH) trials in a changing regulatory landscape
16:40 - 17:00	CLOSE OF CONFERENCE & PRIZE DRAW - ROOM 3	



Breakfast with the Royal Society

Wednesday 4 October, 8am – 9am
Room 14

Learn about the work of the Royal Society, the independent scientific academy of the UK and the Commonwealth.

Discover how the Royal Society could help you collaborate and make connections through our industry fellowship and entrepreneur in residence schemes and industry focussed conference programme.

Find out more at [**royalsociety.org/industry**](https://royalsociety.org/industry)

THE
**ROYAL
SOCIETY**

Image: Microbial fermenter,
courtesy of GSK R&D Stevenage

Session Summary

 #ELRIGDD17

Workshop: Functional Tools to Measure Functional Cells; Case studies in combining the latest advances in stem cell technology with the most advanced instruments in electrophysiology

Wednesday 4th October 2017: 08:30 - 12:30 - ROOM 11A

Stem cell derived neurons offer valuable insights into the mechanisms of disease and drug discovery, as using induced pluripotent stem cell (iPSC) technology gives rise to physiologically relevant neurons, available in large batch sizes. Due to the intricate and complex network activity of iPSC-derived neurons in culture, a high-fidelity assay is needed to fully characterize the electrophysiological profile. Axol Bioscience are experts in the supply of human cell culture systems, specializing in the provision of functionally validated human iPSC derived cells, they have teamed with Alpha MED Scientific, a manufacturer of the MED64, a high-fidelity microelectrode array (MEA) platform that is engineered to detect a broad range of signals. In this workshop, leading researchers will demonstrate the power of high sensitivity MEAs for measuring activity in stem cell derived neurons. This innovative workshop will demonstrate the power of human cell culture systems for disease modeling and drug discovery.

Join us for four presentations from experts in the fields of stem cell biology and microelectrode arrays. A continental breakfast will be available.

WORKSHOP AGENDA		
08:30 – 09:00	Breakfast	
09:00 – 09:10	Gary Allenby, PhD Aurelia Bioscience	Welcome and Introductions
09:10 – 09:50	Nick Clare Axol Bioscience	Relevance of iPSC-derived cells in cell-based screening and drug development
09:50 – 10:30	Eric Hill, PhD Aston University	Modelling neurodegenerative disease using iPSC-derived cells
10:30 - 11:00	COFFEE BREAK	
11:00 – 11:40	Michael Trujillo, PhD Alpha MED Scientific	Innovations in high throughput assays and stem cell technology for drug discovery
11:40 – 12:20	Ikuro Suzuki, PhD Tohoku Institute of Technology	Pharmacological evaluation in human iPSC-derived cortical and sensory neurons using high-throughput MEA system
12:20 – 12:30	Gary Allenby, PhD Aurelia Bioscience	Summary



Session Summary

 #ELRIGDD17

British Pharmacological Society Symposia / Workshop: Driving Drug Discovery through novel industry-academic engagement

Wednesday 4th October 2017: 08:45 - 12:30 - ROOM 11C

The objective of this workshop is to increase awareness of a broad range of activities that have been developed to promote industry-academic drug discovery. As pharma companies streamline their internal operations they are increasingly turning to academia to support their research efforts. Innovative models for collaboration have been developed and are facilitating two-way access to expertise, tools and platforms in a bid to accelerate drug discovery. Pharma companies are differentiating themselves in a bid to become a “partner of choice” for strong academic groups.

The session will highlight a diverse range of truly innovative models of engagement. Talks will be short and will be followed by a guided panel discussion in order to maximise audience participation and engagement.

WORKSHOP AGENDA		
08:45 – 09:00	Steve Rees (AstraZeneca) & Professor Steve Hill (University of Nottingham)	Welcome and Introductions
09:00 – 09:20	Dr Duncan Holmes GlaxoSmithKline	GlaxoSmithKline Drug Discovery Partnerships in Academia
09:20 – 09:40	Dr Garry Pairadeau AstraZeneca	Open Innovation Partnerships at AstraZeneca
09:40 – 10:00	Dr Ann Connolly Johnson & Johnson	Collaborations – The Johnson & Johnson Innovation way
10:00 – 10:20	Dr Olivier Drap Pfizer	Examples of Open Innovation Partnerships at Pfizer
10:20 – 10:30	Dr Anthony Holmes NC3Rs	NC3Rs Presentation
10:30 – 11:00	COFFEE BREAK	
11:00 – 11:20	Dr Richard Butt Apollo Therapeutics	Apollo Therapeutics – a new model enabling drug discovery from academia
11:20 – 11:40	Dr Justin Bryans LifeArc	LifeArc: the Bridge between great science and greater patient impact
11:40 – 12:00	Professor Paul Wyatt Dundee Drug Discovery Unit	The Drug Discovery Unit, Dundee: Collaborative Drug Discovery in an Academic Setting
12:00 – 12:30	All Speakers	Panel Discussion



BRITISH
PHARMACOLOGICAL
SOCIETY

Session Summary



Lab of the Future Workshop: Sponsored by SiLA

Wednesday 4th October 2017: 09:00 - 14:00 - ROOM 11B

From laborious data transfer and incorrect user settings, to poor utilization and uptime, the lab today can be a frustrating place to work! The future promises to be bright, but what will the lab look like? Can our labs benefit from the revolution of the Internet of Things and concepts from Industry 4.0? This innovative workshop held during the ELRIG event will bring together users and suppliers for a fresh discussion on trends and ideas that could influence the lab of the future and make it a more pleasant, safe and productive place to work. In this workshop, we will explore how labs could evolve from user and automation perspectives and the associated challenges with interoperability and data handling that this may bring.

During the workshop, SiLA and ELRIG, together with experts in the field, will present a vision for the future and offer a unique opportunity for attendees to comment and influence how our lab environments could look in the coming years. Join us for 4 highly-interactive linked sessions over a morning, each led by industry leaders, taking us on the journey to the lab of the future. Each session will propose a vision of what is cutting edge in each area and attendees will debate that vision and how best to prepare for it in a fun and interactive way.

WORKSHOP AGENDA		
09:00 – 09:10	Patrick Courtney Director, SiLA Consortium	Welcome and Introductions
09:10 – 09:50	Paul Harper HTS Automation lead, AstraZeneca Andrew Mitchell Automation and Standardization Team, Unilever R&D	Session 1 A vision for the future screening lab: How to address current challenges from users with future technology.
09:50 – 10:30	Rob Harkness Business Development Manager, Peak Analysis & Automation Paul Kendall, Manager MedLab, Festo	Session 2 The art of the possible: How automation is being used to enhance the future lab experience and to learn more from our science
10:30 - 11:00	COFFEE BREAK	
11:00 – 11:40	Gerhard Noelken Business Development Europe, Pistoia Alliance Patrick Courtney Director, SiLA Consortium Burkhard Schaefer Director, BSSN Software	Session 3 Making connectivity a reality: Overcoming the interoperability challenge of sharing data
11:40 – 12:20	Dr. Stephan Heyse Head of Genedata Screener Business Unit, Genedata Mario Bott Project Leader, Fraunhofer-IPA Markus Sebeck Project Manager, EurA	Session 4 Future data visions: Making artificial intelligence science aware to exploit screening data in innovative ways that learn from the past
12:20 – 12:30	SUMMING UP	
12:30 - 13:45	LUNCH - End of Workshop	

Drug Discovery 2017 Exhibitors & Workshops

4titude Ltd. www.4ti.co.uk		Euroscitech www.euroscitech.com		NCIMB Ltd www.ncimb.com	
acCELLerate www.accelerate.me		Formulatrix, Inc. www.formulatrix.com		NMI TT Pharmservices www.nmi-tt.de/pharmservices	
Agilent Technologies www.agilent.com		Genedata AG www.genedata.com/screener		Oncodesign www.oncodesign.com	
Alpha MED Scientific Inc www.med64.com		Greiner Bio One www.gbo.com		PAA www.paa-automation.com	
Axol Bioscience Ltd. www.axolbio.com		Hamamatsu Photonics UK Ltd www.hamamatsu.com		Pelago Bioscience AB www.pelagobio.com	
Beckman Coulter GmbH www.beckman.com/home		HighRes Biosolutions Ltd www.highresbio.com		Pivot Park Screening Centre BV www.pivotparkscreeningcentre.com	
Bigneat www.bigneat.co.uk		Idea Bio-Medical Ltd www.idea-bio.com		Porvair Sciences Ltd www.porvair-sciences.com	
Biosero, Inc www.biosero.com		Image Solutions (UK) Ltd www.imsol.co.uk		Promega UK Ltd www.promega.com	
BioTek Instruments Ltd www.biotek.com		InSphero AG www.insphero.com		ReproCELL www.reprocell.com	
BlueCatBio GmbH www.bluecatbio.com		KBiosystems www.kbiosystems.com		The Royal Society www.royalsociety.org	
British Pharmacological Society www.bps.ac.uk		Labhoo Eventflo www.myeventflo.com		SAL Scientific Ltd www.salscientific.com	
Cambridge Bioscience www.bioscience.co.uk		LabLogic Systems Limited www.lablogic.com		Sartorius Stedim Biotech www.tapbiosystems.com	
Cambridge Research Biochemicals www.crbdiscovery.com/home/		Langton Howarth www.langtonhowarth.co.uk		SB Drug Discovery www.sbdrugdiscovery.com	
Cell Signaling Technology www.cellsignal.com/		LGC - ATCC www.lgcstandards-atcc.org		SiLA - Lab of the Future Workshop www.sila-standard.org	
Cellular Dynamics International www.cellulardynamics.com		Liconic UK www.liconic.com		SLAS www.europe-slas.org	
ChemoMetec www.chemometec.com		LifeArc www.lifearc.org		STEMCELL Technologies www.stemcell.com	
Cisbio www.cisbio.com		Medicines Discovery Catapult www.md.catapult.org.uk		StemTek Therapeutics www.stemtektherapeutics.com	
Collaborative Drug Discovery www.collaborativedrug.com		Meso Scale Discovery www.mesoscale.com		Sygnature Discovery www.sygnaturediscovery.com	
Corning Life Sciences www.corning.com/lifesciences		Miltenyi Biotec GmbH www.miltenyibiotec.com		Takara Bio Europe www.takarabio.com	
DiscoverX www.discoverx.com		Mimetas BV www.mimetas.com		Titian Software Ltd www.titian.co.uk	
ELRIG www.elrig.org		MIP Diagnostics Limited www.mip-dx.com		University of Leicester www.le.ac.uk/research	
ENAMINE Ltd. www.enamine.net		Molecular Devices (UK) Ltd www.moleculardevices.com		UPM-Kymmene Corporation www.growdex.com	
Essen BioScience now part of Sartorius www.essenbioscience.com		NanoTemper Technologies, Ltd www.nanotempertech.com		Wildcat Laboratory Solutions www.wildcatlaboratorysolutions.com	

Platinum Sponsor



Nexcelom Bioscience Ltd
www.nexcelom.co.uk

Gold Sponsors



BMG LABTECH Ltd
www.bmg-labtech.com



Eurofins Pharma Discovery Services
www.eurofins.com/epds



Hamilton Sales & Service UK LTD
www.hamiltoncompany.com



INTEGRA Bioscience Ltd
www.integra-biosciences.com/en



Tecan UK Ltd
www.tecan.com



Labcyte Inc.
www.labcyte.com



Merck
www.merckmillipore.com

Silver Sponsor



IntelliCyt Corporation
www.intellicyt.com

Innovation Zone

Apley Technology Ltd www.apleytechnology.co.uk		DefiniGEN www.definigen.com		Moleculomics Ltd www.moleculomics.com	
Biosystems Technology Ltd www.biosystemstechnology.com		DreamTek www.dreamtek.tv		NC3Rs www.nc3rs.org.uk	
Censo Biotechnologies www.censobio.com		HCS Pharma www.hcs-pharma.com		Peak Proteins Ltd www.peakproteins.com	
CytoSMART www.cytosmart.com		Kirkstall Ltd www.kirkstall.com			

Drug Discovery 2017 Media Partners

BioNow www.bionow.co.uk		Drug Target Review www.drugtargetreview.com		Synbiobeta www.synbiobeta.com	
Biostrata www.biostratamarketing.com		GEN www.genengnews.com		Technology Networks www.technologynetworks.com	
Drug Discovery News www.ddn-news.com		MedChemNet www.medchemnet.com		UKSPA www.scienceparks.co.uk	
Drug Discovery Today www.drugdiscoverytoday.com		N8 Partnership www.n8research.org.uk		UK Pharmacogenetics & Stratified Medicine Network www.uk-pgx-stratmed.co.uk	
Drug Discovery World www.ddw-online.com		Select Science www.selectscience.net		Zyme Communications www.zymecommunications.com	

ELRIG Events 2018

Make sure you are part of these events. Book your place NOW!

For more information please contact the ELRIG team:

Email: info@elrig.org Tel: +44 (0)1904 405 177



Robotics & Automation
Emerging Automation Trends &
Strategies in the Lab Environment
Festo, Stuttgart, Germany
28th February 2018



Research & Innovation
New Biology, New Targets
Homerton College, Cambridge
17th - 18th April 2018



Discovery Technologies:
Mass Spectrometry & Organ on a Chip
Alderley Park, Cheshire
23rd May 2018



Drug Discovery
Drug Discovery for Small & Large Molecules
Excel Arena, London
9th - 10th October 2018



Pharmaceutical Flow Cytometry & Imaging
Flow Cytometry & Imaging from single cell
to the patient
GlaxoSmithKline, Stevenage
14th - 15th November 2018